Can a Smaller Plasmid Produce Huge Benefits? The Power of Small

Phacilitate
20 September 2022
SHARE NOW
Allogeneic
Cell Therapy
Clinical Trials
Gene Therapy
Logistics
Partnering
Patient Access & Engagement
Scaling Up

08:00 PDT | 11:00 EDT | 16:00 GMT
Thursday 6th October 2022
REGISTER NOW | MEET THE PANEL

Optimizing gene payload begins with plasmid design.

That’s where the Nanoplasmid™ vector platform has shown benefits over traditional plasmids. The small (<500bp) backbone reduces potential plasmid silencing in target cells and tissues compared to plasmids containing up to 1.5–2kb of bacterial regions and junk DNA.

With benefits across applications including transposons, HDR/CRISPR, viral vectors, and mRNA; nanoplasmids are designed to replace antiquated bacterial backbones, while eliminating antibiotic marker that can cause regulatory concerns.

Join us for a discussion on how nanoplasmid benefits may accelerate therapies.

WHAT TO EXPECT

Part 1: The panel will address the unique opportunities associated with using nanoplasmids over traditional plasmids (dependent on application), including:

  • AAV application: safety benefits.
  • Lentiviral application: significant increase in viral titres and additional safety benefits.
  • Cell therapy: reduced cell death which leads to improved performance and longevity.
  •  

Part 2: The panel answers audience questions with an interactive Q&A.

MEET THE PANEL


Jim Williams
Chief Scientific Officer, VP R&D
Nature Technology Corporation

 


Emma Bjorgum
VP, DNA Client Services
Aldevron

 


Ellen Shafer
Senior Director of Marketing & Communications
Aldevron

 


Tyler Koziek
Research and Development Scientist
Aldevron

 

This webinar will be produced in partnership with Aldevron